Axsome Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Axsome Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 72.5% bzw. 38.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 117.9% betragen.

Wichtige Informationen

72.5%

Wachstumsrate der Gewinne

71.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	24.0%
Wachstumsrate der Einnahmen	38.8%
Zukünftige Eigenkapitalrendite	117.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Dec 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Recent updates

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Dec 23

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:AXSM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,053	146	186	208	13
12/31/2025	647	-104	-53	-62	17
12/31/2024	384	-261	-146	-203	17
9/30/2024	338	-311	-133	-133	N/A
6/30/2024	291	-309	-168	-167	N/A
3/31/2024	251	-296	-193	-193	N/A
12/31/2023	271	-239	-146	-145	N/A
9/30/2023	223	-202	-143	-142	N/A
6/30/2023	182	-184	-112	-111	N/A
3/31/2023	145	-159	-90	-90	N/A
12/31/2022	50	-187	-117	-117	N/A
9/30/2022	26	-160	-118	-118	N/A
6/30/2022	9	-150	-123	-122	N/A
3/31/2022	N/A	-141	-114	-114	N/A
12/31/2021	N/A	-130	-109	-108	N/A
9/30/2021	N/A	-126	-100	-100	N/A
6/30/2021	N/A	-114	-89	-89	N/A
3/31/2021	N/A	-100	-82	-82	N/A
12/31/2020	N/A	-103	-79	-78	N/A
9/30/2020	N/A	-99	-75	-75	N/A
6/30/2020	N/A	-95	-70	-70	N/A
3/31/2020	N/A	-90	-60	-60	N/A
12/31/2019	N/A	-68	-46	-46	N/A
9/30/2019	N/A	-53	-39	-39	N/A
6/30/2019	N/A	-42	-34	-34	N/A
3/31/2019	N/A	-37	-33	-33	N/A
12/31/2018	N/A	-31	-30	-30	N/A
9/30/2018	N/A	-29	-27	-27	N/A
6/30/2018	N/A	-27	N/A	-27	N/A
3/31/2018	N/A	-26	N/A	-27	N/A
12/31/2017	N/A	-29	N/A	-26	N/A
9/30/2017	N/A	-29	N/A	-27	N/A
6/30/2017	N/A	-30	N/A	-26	N/A
3/31/2017	N/A	-29	N/A	-24	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-23	N/A	-16	N/A
6/30/2016	N/A	-21	N/A	-13	N/A
3/31/2016	N/A	-16	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-7	N/A
6/30/2015	N/A	-6	N/A	-6	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-6	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AXSM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: AXSM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: AXSM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: AXSMDie Einnahmen des Unternehmens (38.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9.2% pro Jahr).

Hohe Wachstumseinnahmen: AXSMDie Einnahmen des Unternehmens (38.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AXSMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (117.9%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/12/26 03:55
Aktienkurs zum Tagesende	2024/12/26 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Axsome Therapeutics, Inc. wird von 27 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Difei Yang	Aegis Capital Corporation
Joel Beatty	Baird
Esther Lannie Hong	Berenberg

Axsome Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 25%

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 21%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates increase by 45%

Recent updates

Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Axsome: AXS-07 And Its Upcoming Second PDUFA

Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Axsome Therapeutics: Lots Of Moving Parts

Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Consensus EPS estimates fall by 27%

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023